SYM FINANCIAL Corp Takes $216,000 Position in IQVIA Holdings Inc. $IQV

SYM FINANCIAL Corp purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, Holdings Channel reports. The firm purchased 1,368 shares of the medical research company’s stock, valued at approximately $216,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC increased its stake in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new stake in IQVIA during the first quarter worth about $33,000. Trust Co. of Toledo NA OH acquired a new stake in IQVIA during the second quarter worth about $39,000. Finally, J.Safra Asset Management Corp increased its position in IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

IQV opened at $218.26 on Wednesday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $225.91. The firm has a market capitalization of $37.10 billion, a P/E ratio of 31.59, a PEG ratio of 2.39 and a beta of 1.32. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The stock has a fifty day moving average of $195.48 and a 200-day moving average of $172.51.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. UBS Group increased their target price on IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Truist Financial lifted their target price on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Mizuho lifted their price target on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Robert W. Baird boosted their price objective on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Finally, Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $234.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.